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Abstract
Introduction: Nectins are a family of integral protein molecules involved in the formation of functioning Adherens and Tight
Junctions (TJ). Aberrant expression is associated with cancer progression but little is known how this effects changes in cell
behaviour. This study aimed to ascertain the distribution of Nectins-1 to -4 in human breast cancer and the effect on
junctional integrity of Nectin-3 modulation in human endothelial and breast cancer cells.
Methods: A human breast tissue cohort was processed for Q-PCR and immunohistochemistry for analysis of Nectin-1/-2/-3/-
4. Nectin-3 over-expression was induced in the human breast cancer cell line MDA-MB-231 and the human endothelial cell
line HECV. Functional testing was carried out to ascertain changes in cell behaviour.
Results: Q-PCR revealed a distinct reduction in node positive tumours and in patients with poor outcome. There was
increased expression of Nectin-1/-2 in patients with metastatic disease, Nectin-3/-4 was reduced. IHC revealed that Nectin-3
expression showed clear changes in distribution between normal and cancerous cells. Nectin-3 over-expression in MDA-MB-
231 cells showed reduced invasion and migration even when treated with HGF. Changes in barrier function resulted in
MDAN3 cells showing less change in resistance after 2h treatment with HGF (p,0.001). Nectin-3 transformed endothelial
cells were significantly more adhesive, irrespective of treatment with HGF (p,0.05) and had reduced growth. Barrier
function revealed that transformed HECV cells had significantly tighter junctions that wildtype cells when treated with HGF
(p,0.0001). HGF-induced changes in permeability were also reduced. Overexpression of Nectin-3 produced endothelial cells
with significantly reduced ability to form tubules (p,0.0001). Immunoprecipitation studies discovered hitherto novel
associations for Nectin-3. Moreover, HGF appeared to exert an effect on Nectin-3 via tyrosine and threonine
phosphorylation.
Conclusions: Nectin-3 may be a key component in the formation of cell junctions and be a putative suppressor molecule to
the invasion of breast cancer cells.
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Introduction
The Nectins are a family of immunoglobulin-like cell adhesion
molecules that have long been thought of as essential components
for the formation of cell–cell adhesions and regulators of cellular
functions that include cell polarization, differentiation, movement,
proliferation and survival [1]. The Nectin family is comprised of
four members, Nectin-1 (PVRL1 (Poliovirus receptor-related 1),
HveC (herpesvirus entry mediator C), CD111 (Cluster of
Differentiation 111)), Nectin-2 (PVRL2 (Poliovirus receptor-
related 2), HveB (herpesvirus entry mediator B), CD112 (Cluster
of Differentiation 112), Nectin-3 (PVRL3 (Poliovirus receptor-
related 3), CD113) and Nectin-4. The four members of the Nectin
family are thought to be ubiquitously expressed and have a
number of spliced variants.
Each Nectin has a c-terminal motif of 4 amino acids (E/A-K-Y-
V) that interacts with the PDZ domain of afadin. Nectin-1 has two
splicing variants, nectin-1a and –1b/HigR [2–3]. Nectin-2 also
has two splicing variants, nectin-2a and –2d [4–5]. Nectin-3 has
three splicing variants nectin-3a, -3b and –3d [6]. The extracel-
lular regions of splicing variants are identical, but their
transmembrane regions and cytoplasmic regions are different.
The cytoplasmic regions of nectin-1a, -2a, -2d, -3a and 3d have a
C-terminal conserved motif of 4 amino acid residues (E/A-X-Y-
V), which interact with the PDZ domain of afadin through which
they are liked to the actin cytoskeleton [7]. The physiological role
of Nectins has yet to be satisfactorily clarified [8], although work
suggests that they may play a key role in the proper organisation of
both adherens junctions (AJ) and tight junctions (TJ) [9].
These Ca (2+)-independent cell adhesion molecules first form
cell-cell adhesions where cadherins are recruited, forming
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adherens junctions in epithelial cells and fibroblasts. In addition,
Nectins recruit claudins, occludin, and junctional adhesion
molecules (JAM’s) to the apical side of AJs, forming TJs in
epithelial cells. All four Nectin family members have one
extracellular region with three Ig-like loops, one transmembrane
segment and one cytoplasmic tail [10]. The formation of cis-
dimers is necessary for the formation of Nectin trans-dimers.
Nectin-3 was first described by Satoh-Horikawa [6] as a member
of the Nectin family. The first Ig-like loop of Nectin-3 is essential
and sufficient for the formation of trans-dimers with Nectin-1, but
the second Ig-like loop of Nectin-3 was furthermore necessary for
its cell-cell adhesion activity [10].
Although Nectins were initially thought to be only localised at
AJs, studies have suggested that a role in the formation or
organisation of TJs may be found. Reymond et al. [11] showed
that Nectin-3 (PRR3) interacts with afadin by interaction of the C-
terminal to the PDZ domain of afadin. Inagaki et al. [12] have
shown that the Nectin-afadin system is able to recruit ZO-1 to the
Nectin-based cell-cell adhesion sites in non-epithelial cells that
have no TJs.
Besides their role in physiology, Nectins have been involved in
different pathological processes in humans where they serve as
virus receptors (poliovirus and herpes simplex virus), they are
involved in orofacial malformation (CLPED1) and recently they
have been described as markers, actors and potential therapeutic
targets in cancer [13–14]. Nectin-2 and Nectin-4 are often
overexpressed in tumours, and are associated with a poor
prognosis [14]. Indeed, Nectin-2 has been found to be over-
expressed in clinical breast and ovarian cancer tissues by using
gene expression profile analysis and immunohistochemistry studies
[15]. Nectin-2 was over-expressed in various cancer cell lines as
well [13]. Interestingly, a polyclonal antibody specific to Nectin-2
suppressed the in vitro proliferation of OV-90 ovarian cancer cells,
which express endogenous Nectin-2 on the cell surface. The anti-
Nectin-2 antibpdies generated were classified into 7 epitope bins.
The anti-Nectin-2 mAbs demonstrated antibody-dependent cellu-
lar cytotoxicity (ADCC) and epitope bin-dependent features such
as the inhibition of Nectin-2-Nectin-2 interaction, Nectin-2-
Nectin-3 interaction and in vitro cancer cell proliferation. A
representative anti-Nectin-2 mAb in epitope bin VII, Y-443,
showed anti-tumour effects against OV-90 cells and MDA-MB-
231 breast cancer cells in mouse therapeutic models, and its main
mechanism of action appeared to be ADCC. These findings
suggest that Nectin-2 is a potential target for antibody therapy
against breast and ovarian cancers [15].
The expression of Nectin-4 was increased in ovarian cancer
compared with normal ovaries. Reverse transcriptase-polymerase
chain reaction (RT-PCR) and quantitative RT-PCR validated the
overexpression of Nectin-4 messenger RNA in ovarian cancer
compared with normal ovarian cell lines and tissues. Protein levels
were elevated in ovarian cancer cell lines and tissue compared with
normal ovarian cell lines. Cleaved Nectin-4 was detectable in a
number of patient serum samples and in patients with benign
gynecologic diseases with high serum CA125 levels, Nectin-4 was
not detected in the majority of cases, suggesting that it may serve
as a potential biomarker that helps discriminate benign gyneco-
logic diseases from ovarian cancer in a panel with CA125. Fabre-
Lafay et al. [16] also found Nectin-4 not to be detected in normal
breast epithelium. By contrast, Nectin-4 was expressed in 61% of
ductal breast carcinoma vs 6% in lobular type. Expression of
Nectin-4 strongly correlated with the basal-like markers EGFR,
P53, and P-cadherin, and negatively correlated with the luminal-
like markers ER, PR and GATA3. All but one ER/PR-negative
tumour expressed Nectin-4. The detection of Nectin-4 in serum
improved the follow-up of patients with MBC as the association of
CEA/CA15.3/Nectin-4 allowed monitoring of 74% of these
patients compared to 67% with the association CEA/CA15.3
[16]. Serum Nectin-4 was also found to be a marker of therapeutic
efficiency and correlates, in 90% of cases, with clinical evolution.
The authors concluded that Nectin-4 was a new tumour-
associated antigen for breast carcinoma and a new bio-marker
whose use could help refine breast cancer taxonomy and improve
patient follow-up [16].
In lung cancer, Maniwa et al. [17] demonstrated that of 127
patients, 25% showed membranous expression of Nectin-3, and
others showed negative or cytoplasmic expression. Membranous
expression of Nectin-3 was found to be a prognostic factor for
decreased overall survival and Multivariate Cox proportional
hazards model analyses revealed that membranous expression of
Nectin-3 was an independent prognostic factor. In tumours
expressing membranous Nectin-3, some did not co-localize with
E-cadherin and these patients showed poorer prognosis than other
patients for overall survival. Conversely, membranous expression
of Nectin-3 with E-cadherin co-localization was found to associate
with good prognosis of patients.
Breast cancer is the most common cancer in women worldwide
and is the principle cause of death from cancer among women
globally. Despite the high incidence rates, in Western countries,
89% of women diagnosed with breast cancer are still alive 5 years
after their diagnosis, which is due to detection and treatment [18].
The UK and USA have one of the highest incidence rates
worldwide (together with the rest of North America and Australia/
New Zealand), making these countries a priority for breast cancer
awareness (Worldwide Breast Cancer statistics). Breast cancer has
been the most common cancer in the UK since 1997, despite the
fact that it is rare in men (Cancer Research UK Statistics). It is by
far the most common cancer among women in the UK (2010),
accounting for 31% of all new cases of cancer in females. In 2010,
there were 49,961 new cases of breast cancer in the UK with
49,564 (99%) in women and 397 (less than 1%) in men, giving a
female to male ratio of around 125 to 1. Despite rising survival
rates, mainly due to earlier detection and better treatments, many
of the cellular processes underlying the disease remain to be
determined. Aberrant expression of Nectins has been associated
with cancer and evidence has shown that Nectins may be integral
to the correct functioning of TJs. TJs in epithelial cells act as cell-
cell adhesion structures and govern paracellular permeability.
Disruption of these functions often leads to the dissociation and
metastasis of cancer cells.
There has not been, to date, a study examining the distribution
and expression of all four Nectins in human breast cancer and
further information on the roles of Nectin-3 have yet to be
determined. This study aimed to ascertain the distribution of
Nectins in human breast cancer and to determine the role that
Nectin-3 may have in regulating cell behaviour in human breast
cancer and endothelial cells.
Materials and Methods
Ethics statement
All research involving human tissues was under the ethical
approval of the local ethics committee (Bro Taf Local Research
Ethics Committee (Panel B) for the Bro Taf Health Board, Cardiff,
UK, issued 10/12/2001, reference 01/4303). All data was
analysed anonymously and informed verbal consent given. As
the tissues were collected before the introduction of the Human
Tissue Act, UK, 2004, no written consent was necessary and
documentary measures not required. The project license (PPL 30/
Nectins and Breast Cancer
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2591) under which all in vivo work was carried out was approved by
both the Cardiff University School of Medicine JBIOS Committee
and the UK Home Office under the Animals (Scientific
Procedures) Act 1986, as issued by the Secretary of State for the
UK Home Office. In vivo work was carried out under the strict
guidelines of the UK Home Office to ensure that the 3R’s were
strictly adhered to. Thus, the minimum number of animals was
used in the experiment, with the minimum of suffering and
maximum attention to animal welfare. The maximum severity
band allowed was moderate, although the procedures carried out
in this work were ostensibly only mild. Animals were checked daily
and their behavior and health monitored. Animals were weighed
and measured twice weekly to ascertain loss of health (as
determined by weight loss greater than 20% or tumour burden
greater than 1cm3). Adverse effects resulted in sacrifice via UK
Schedule One procedures.
Reagents and antibodies
Nectin-1, -2 and -3 (A is C-19; B is K-20) antibodies were
obtained from Santa-Cruz Biotechnologies Inc. (Santa Cruz, USA)
as was anti-actin (sc-8432), anti-Occludin, ZO-1, ZO-2, ZO-3,
AF6, Ezrin, Moesin, Radixin, E-cadherin, SIPA-1, a-catenin, b-
catenin, c-catenin, Axin, MAGI-1, MAGI-2, MAGI-3, CAR,
Tricellulin and ROCKI. Secondary peroxidase conjugated
antibodies were from Sigma (Sigma-Aldrich, Dorset, UK).
Cell lines and culture conditions
The human breast cancer cell lines MDA-MB-231 and MCF-7
were obtained from ECACC and the HECV endothelial cell line
from the Interlab Cell Line Collection (ICLI), Naples, Italy and
were routinely maintained in Dulbecco’s Modified Eagle Medi-
um/F12 (DMEM/F12) (Sigma-Aldrich, Dorset, UK) supplement-
ed with 10% fetal calf serum (FCS), penicillin and streptomycin
(Sigma-Aldrich, Dorset, UK). The cells were incubated at 37uC,
5% CO2 and 95% humidity.
Human breast specimens
The human breast cancer tissue cohort consisted of a total of
133 breast samples obtained from breast cancer patients (106
breast cancer tissues and 27 associated background or related
normal tissue), with the consent of the patients and local ethical
committee approval (Bro Taf Healthboard). The tissues were
verified by a pathologist as normal background and cancer
specimens, and it was confirmed that background samples were
free from tumour deposit. The tissues were immediately frozen in
liquid nitrogen following excision.
RNA extraction and Reverse Transcription-Polymerase
Chain Reaction (RT-PCR)
Cells were grown to confluence in a 25 cm3 flask before RNA
was extracted using total RNA isolation (TRI) reagent and
following the protocol provided (Sigma-Aldrich, Dorset, UK).
RNA was converted to cDNA using iScript cDNA synthesis kit
(Primer Design Ltd., Southampton, UK). Following cDNA
synthesis, samples were probed using actin primers to check the
quality of the cDNA and confirm uniform levels within each
sample together with those specific for the transcript (full primer
sequences are outline in Table 1). Conventional PCR was
performed using a T-Cy Thermocycler (Beacon Technologies
Ltd., The Netherlands) using REDTaqH ReadyMixTM PCR
Reaction mix (Sigma-Aldrich, Dorset, UK). Cycling conditions
were as follows: 94uC for 5 min, 94uC for 30 s, 55uC for 30 s,
72uC for 30 s and the final extension phase at 72uC for 7 min for
36 cycles. The PCR products were separated on a 2% agarose gel
and electrophoretically separated. The gel was then stained with
Table 1. Primers for PCR used in this study.
Primer name Sequence (59-39)
b-actin bactinF- atgatatcgccgcgctcg; bactinR- cgctcggtgaggatcttca
GAPDH GAPDHF1- aaggtcatccatgacaactt; GAPDHR1- ggctgcttttaactgggta
Nectin-1 NectinF1- attacgggaaaaagacacag
Nectin-2 Nectin2F1- tgatacctgtgaccgtctct; Nectin2R1- aggatgaaggccaaggac
Nectin-3 Nectin3F1- agttatggagggtgacttga; Nectin3R1- atggctgctactgtttcatt
Nectin-4 Nectin4F1- aaggatcacccacatcct; Nectin4R1- acataggccacctgctt
Nectin3FX1* Nectin3FX1- gcaaagcacaactttcctc
Nectin3FX2* Nectin3FX2- ggaaaatacatctgcaaagc
Nectin3FX3* Nectin3FX3- atgaaacagtagcagccatt
Nectin3FX4* Nectin3FX4- atggcgcggaccctgcggc
Nectin3FX5* Nectin3FX5-cttcattttgtccatccatt
Nectin3FX6* Nectin3FX6- tggctggaatattctgctat
Nectin3RX Nectin3RX- ctaaacataccactccctcct
Nectin-1Z** NectinF1- attacgggaaaaagacacag; Nectin1ZR- acgaacctgaccgtacaagttcttggtcaccctttct
Nectin-2Z** Nectin2F1- tgatacctgtgaccgtctct; Nectin2ZR- actgaacctgaccgtacaagctcactcggattatatgc
Nectin-3Z** Nectin3F- agttatggagggtgacttga; Nectin3ZR- actgaacctgaccgtacacattctttccccatactgt
Nectin-4Z** Nectin4F1- aaggatcacccacatcct; Nectin4ZR- actgaacctgaccgtacacacttgagcatagctccttc
GADPHZ** GAPDH2F- ctgagtacgtcgtggagtc; GAPDHZR2- actgaacctgaccgtacacagagatgatgacccttttg
b-actinZ** bactinZF- ggacctgactgactacctca; bactinZR- actgaacctgaccgtacaagcttctcctt
*Nectin3FX1 to FX6 versus Nectin3RX; **Z primers for Q-PCR.
doi:10.1371/journal.pone.0082696.t001
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ethidium bromide prior to examine under ultraviolet light and
photographs taken. The primers used are shown in Table 1.
Real-time quantitative Polymerase Chain Reaction
(Q-PCR)
The Amplifluor system was used to detect and quantify
transcript copy number of Nectin-1, Nectin-2 and Nectin-3 in
tumour and background samples. Primers were designed by
Beacon Designer software, which included a complementary
sequence to universal Z probe (Intergen, Inc.). Each reaction
contains 10 pmol reverse primer (which has the Z sequence),
10 pmol of FAM-tagged universal Z probe (Intergen, Inc.) and
cDNA (equivalent to 50 ng RNA) (primer sequences are shown in
Table 1). Sample cDNA was amplified and quantified over a large
number of shorter cycles using an iCyclerIQ thermal cycler and
detection software (BioRad laboratories, Hammelhempstead, UK)
under the following conditions: an initial 5 minute 94uC period
followed by 60 cycles of 94uC for 10 seconds, 55uC for 15 seconds
and 72uC for 20 seconds. Detection of GAPDH copy number
within these samples was later used to allow further standardisa-
tion and normalisation of the samples. Q-PCR primers are shown
in Table 1.
Over-expression of Nectin-3 in MDA-MB-231 breast
cancer cells and HECV endothelial cells
A range of normal human tissues were screened for Nectin-3.
Normal breast tissue was chosen for endogenous expression of
Nectin-3. The human breast cancer cell line MDA-MB-231 and
the human endothelial cell line were chosen for introduction of the
Nectin-3. The gene, after amplification from breast tissue cDNA
was cloned into aPEF6/V5-His TOPO TA plasmid vector
(Invitrogen Ltd., Paisley, UK) before electroporation into the
cells. Expression of the gene was confirmed by RT-PCR. The
Nectin-3 expression construct and empty plasmid were, respec-
tively, used to transfect MDA-MB-231 and HECV cells by
electroporation. Stably transfected cells were then used for
subsequent assays after being tested at both transcriptional and
translational level. Those cells containing the expression plasmid
and displaying enhanced Nectin-3 expression were designated
MDAN3 and HECVN3, those containing the closed pEF6 empty
plasmid and used as control cells were designated MDApEF6
and HECVpEF6 and unaltered wild type were designated
MDAWT and HECVWT. Expression primers were: Necti-
n3EXF1: 59-atggcgcggaccctgcggccgtc-39 and Nectin3RX 59-
ctaaacataccactccctcct-39.
Construction of hammerhead ribozyme transgene
targeting human Nectin-3
Hammerhead ribozymes that specifically target human Nectin-
3 were constructed based on its secondary structure. Touch down
PCR was used to generate PCR-based ribozymes which were then
cloned into a pEF6/V5-His vector (selection markers: ampicillin
and blasticidin, for prokaryotic and mammalian cells respectively),
and amplified in Escherichia coli, purified, verified and used for
electroporation into both MDA-MB-231 and MCF-7 human
breast cancer cells lines. The targets were as follows: Nectin3-
ribR1-actagtacaatgcctgtcaaaacttttcgtcctcacggact and Nectin3rib1F-
ctgcagaacggtgagatatgccttgctgatgagtccgtgagga.
SD-PAGE, Western blotting and co-immunoprecipitation
Cells were grow to confluence, detached and lysed in HCMF
buffer containing 0.5% SDS, 0.5% Triton X-100, 2 Mm CaCl2,
100 mg/ml phenylmethylsulfonyl fluoride, 1 mg/ml leupeptin,
1 mg/ml aprotinin and 10 Mm sodium orthovanadate for 1 hour,
sample buffer was added and the protein boiled at 100uC for
5 min before being spun at 13,000 g for 10 min to remove
insolubles. Protein concentration was quantified using Bio-Rad
Protein Assay kit (Bio-Rad Laboratories, Hertfordshire, UK).
Equal amounts of protein from each cell sample were added onto
a 10% or 15% (depending on protein size) acrylamide gel and
subjected to electrophoretic separation. The proteins were
transferred onto nitrocellulose membranes which were blocked
and probed with specific primary antibodies (1:500), following with
peroxidase-conjugated secondary antibody (1:1000). Protein bands
were visualized with Supersignal West Dura system (Perbio
Science UK Ltd., Cramlington, UK) and detected using a
CCD-UVIprochemin system (UVItec Ltd., Cambridge, UK).
Co-immunoprecipitation samples were prepared as follows: cell
lysate of the protein of interest was probed with primary antibodies
(1:100 dilution) and placed on a rotating wheel for 2 hour allowing
primary antibodies to bind to their targets. One hundred
microlitres of conjugated A/G protein agarose beads (Santa-Cruz
Biotechnologies Inc., USA) were added to each sample to make
the antibody-protein complex insoluble, followed by overnight
incubation on the rotation wheel. The supernatant was discarded
and the pellet was washed in 200 ml of lysis buffer and resuspended
in 200 ml of 2X Lamelli sample buffer concentrate (Sigma-Aldrich,
Dorset, UK), then denatured for 5 minutes by boiling at 100uC.
Trans-epithelial resistance (TER) and Paracellular
Permeability
Cells were seeded into 0.4 mm transparent pore size inserts
(Greiner bio-one, Stonehouse, UK) at a density of 50,000 cells in
200 ml of medium within 24 well plates, grown to confluence, the
medium removed and replace with fresh Dulbecco’s Modified
Eagle’s medium containing 15 Mm Hepes, L-Glutamine (Lonza
Laboratories, Verviers, Belgium). Medium alone was added to the
base of the wells (control) or with 40 or 50 ng/ml HGF [19].
Resistance across the layer of cells was measured using an EVON
volt-ohmmeter (EVOM, World Precision Instruments, Aston,
Herts, UK), equipped with static electrodes (WPI, FL, USA) for a
period of 4 h. Paracellular permeability (PCP) was determined
using fluorescently labeled dextran FITC-Dextran 40, molecular
weight being 40 kDa. Human breast cancer cells were prepared
and treated as in the TER study, but with the addition of Dextran-
40 to the upper chamber. Medium from the lower chamber was
collected for intervals up to 2 h after addition of HGF. The
relative fluorescence from these collections was read on a
multichannel fluorescence reader (Denly, Sussex, UK).
In vitro cell growth assay
MDA-MB-231 and HECV cells were seeded into a 96 well plate
at a density of 3,000 cells/well to obtain density readings after 1
day, 2 days, 3 days, 4 days and 5 days. Within each experiment
four duplicates were set up. After appropriate incubation periods,
cells were fixed in 4% formaldehyde in BSS for 5–10 minutes
before staining for 10 minutes with 0.5% (w/v) crystal violet in
distilled water. The crystal violet was then extracted from the cells
using 10% acetic acid. Absorbance was determined at a
wavelength of 540 nm on a plate reading spectrophotometer.
In vitro cell matrix adhesion assay
The cell-matrix attachment was carried out as previously
described method [19]. Briefly, 45,000 cells were seeded onto the
Matrigel basement (10 mg/well) membrane in 200 ml of normal
medium and incubated at 37uC with 5% CO2 for 40 minutes.
Nectins and Breast Cancer
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After the incubation period, the medium was aspirated and the
membrane washed 5 times with 150 ml of BSS to remove the non-
attached cells, then fixed in 4% formaldehyde (v/v) in BSS for
10 minutes before being stained in 0.5% crystal violet (w/v) in
distilled water. The number of adherent cells were counted from 5
random fields per well and 5 duplicate wells per sample, under a
microscope.
In vitro invasion cell assay
Cell culture inserts (BD FalcomTM Cell Culture Inserts, BD
Bioscience, Erembodegem, Belgium) were placed into a 24-well
plate using forceps and coated in Matrigel (BD Biosciences,
Oxford, UK). The working solution of Matrigel was prepared at a
concentration of 0.5 mg/ml, adding 100 ml to each insert and
allowed to dry overnight. Once dried the inserts were rehydrated
in 100 ml sterile water for 1 hour. The water was then aspirated
and cells were seeded in the inserts over the top of the artificial
basement membrane at a density of 30,000 cells in 200 ml per well.
The plates were then incubated for 3 days at 37uC at 5% CO2.
After the incubation period, the Matrigel layer together with the
non-invasive cells was cleaned from the inside of the insert with a
tissue paper. The cells which had migrated through the pores and
invaded into the Matrigel, were fixed in 4% formaldehyde (v/v)
in BSS for 10 minutes before being stained in 0.5% crystal violet
(w/v) in distilled water. The cells were then visualized under the
microscope under 640 magnification, 5 random fields counted
and duplicate inserts used for each test sample.
In vitro Cytodex-2-bead motility assay
Cells were pre-coated onto Cytodex-2 beads (GE Healthcare,
Cardiff, UK) for 2 hours. The medium was aspirated and the
beads washed in medium to remove non-adherent or dead cells.
The beads were resuspended in 5 ml of medium. Cell were
aliquoted into a 24-well plate, 5 duplicate wells per sample
(300 ml/well), and incubated overnight. Following incubation, cells
that had migrated from the Cytodex-2 beads and adhered to the
base of the wells were washed gently in BSS, fixed in 4%
formaldehyde (v/v) in BSS for 10 minutes before being stained in
0.5% crystal violet (w/v) in distilled water. Five random fields per
well were counted under the microscope.
Tubule formation assay
A volume of 100 ml serum free medium containing 250 mg
Matrigel (250 mg/well) was seeded in a 96 well plate and left to gel
in an incubator for 30 minutes, followed by a heating oven until
dry. Before use, the Matrigel was rehydrated in 100 ml of serum
free medium and cells seeded at a density of 40,000 cells/well.
Following incubation at 37uC for 1 hour, the medium was
aspirated and a second layer of Matrigel was added followed by
incubation at 37uC 3 for 30 minutes to gel. Medium was then
added and the cells left overnight to allow tubules to form.
In vivo development of mammary tumours
Athymic nude mice (nu/nu) were purchased from Charles River
Laboratories (Charles River Laboratories, Kent, UK) and
maintained in filter top units according to Home Office
regulations and ethical requirements. Each group of mice
consisted of 5 mice and each mouse was injected with a mix of
26106 cancer cells in 100 ml in a 0.5 mg/ml Matrigel suspension
in both flanks. Two groups were included: MDA-MB-231pEF6 and
MDA-MB-231N3exp. The mice were weighed and tumour size
measured twice weekly using a vernier calipers under sterile
conditions. Those mice that developed tumours exceeding 1 cm3
or suffered 25% weight loss during the experiment were
terminated under Schedule 1 according to the UK Home Office
and the UK Coordinating Committee on Cancer Research
(UKCCCR) instructions. Tumour volume was determined using
the following formula: tumour volume = 0.5236width26length.
Statistical analysis
Statistical analysis was performed by MINITAB version 13.32
(Minitab Inc. State College, PA, USA) using a two-sample student
t-test and the non-parametric Mann-Whitney confidence interval
test or Kruskal-Wallis, where appropriate.
Results
Expression of Nectins in human breast cancer at the
transcript level
Patient tissue was prepared for both mRNA and protein
analysis. Q-PCR revealed that all four Nectins had elevated levels
in tumour samples, although significance was not reached (Nectin-
1: tumour 304+/296 versus background 213+/2103); Nectin-2:
tumour 89.4+/272.1 versus background 1.820+/20.727; Nectin-
3: tumour 1507+/2953, background 250+/2117; Nectin-4:
tumour 0.242+/20.122 versus background 0.134+/20.106).
However, nodal status showed that whilst Nectin-1 and -4 were
increased in node positive tumours (Nectin-1 node negative 189+/
242, node positive 466+/2214; Nectin-4 node negative 0.149+/
20.10, node positive 0.38+/20.25), both Nectin-2 and -3 were
reduced (Nectin-2 node negative 154+/2130, node positive
11.1+/29.1; Nectin-3 node negative 2458+/21761, node positive
425+/2198), Figure 1A and B.
Nectin-1 was found to have higher expression with increasing
NPI (Nottingham Prognostic Indicator), tumour grade and TNM
status (tumour-nodal involvement) as was Nectin-4 (Nectin-1:
NPI1 188.7+/242 versus NPI3 560+/2500; Grade1 191.3+/
278.5 versus Grade3 1313+/21051; TNM1 266+/245 versus
TNM3 1313+/21051, Nectin-4: NPI1 0.149+/20.104 versus
NPI3 0.323+/20.201; Grade1 0.0265+/20.024 versus Grade3
0.252+/20.2; TNM1 0.00001+/20.000 versus TNM3 0.252+/
20.24). Expression of NEctin-2 was reduced with increasing NPI
(NPI1 154+/2130 versus NPI3 32.7+/231.3) and Grade (Grade1
29+/226.8 versus Grade3 4.85+/21.93) but was increased with
TNM status (TNM1 0.0154+/20.013 versus TNM3 4.85+/
21.93). Nectin-3 was reduced with increasing NPI (NPI1 2458+/
21761 versus NPI3 301+/2216) and Grade (Grade1 1701+/
21517 versus Grade3 687+/2408) and was also increased in
increasing TNM status (TNM1 500.5+/292.5 versus TNM3
687+/2408).
Nectin expression and patient survival
When patient outcome was analysed, it was seen that Nectin-1
was elevated in patients that had died from breast cancer, and all
poor outcomes overall (Figure 1C). In comparison, Nectin-2, -3
and -4 were all reduced in patients with metastatic disease and
those who had died of the disease (Figure 1C and 1D). When
looking more closely at those with metastatic disease, we found
that this was also true for metastasis to bone (Figure 1 E and 1F),
however, these did not reach significance.
Long-term survival curves were calculated using Kaplan-Meier
survival curves (Fig. 1G). Patients with higher levels of Nectin-1
had shorter survival than patients with low levels (not significant);
high mean survival 114.98 months (91.83–138.12 months, 95%
CI) versus low mean survival 133.66 months (121.52–145.81
months, 95% CI, cut-offs as previously determined (Martin et al.
2004). This was true of Nectin-2 (high mean survival 132.46
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months (113.10–151.22 months, 95% CI) versus low mean
survival 127.86 months (117.64–138.07 months, 95% CI) and
Nectin-3 (high mean survival 137.88 months (127.20–148.55
months, 95% CI) versus low mean survival 117.74 months (99.20–
136.29 months, 95% CI). For Nectin-4, higher levels were
significantly associated with better survival (high mean survival
138.82 months (128.83–148.81 months, 95% CI) versus low mean
survival 97.58 months (73.24–121.93 months, 95% CI,
p = 0.0274).
Nectin expression and estrogen receptor status
Levels of Nectin-1 were elevated in estrogen receptor positive
(ER+) tumours, when compared to estrogen negative (ER2) (ER+
609+/2280 versus ER2 152.5+/229.7). However, estrogen
receptor b positive (ERb+) had lower levels of Nectin-1 than
estrogen receptor b negative (ERb2) (ERb+ 165.6+/273.7 versus
ERb2 344+/2121). For Nectin-2, ER2 levels were higher than
ER+, whilst ERb+ were lower than ERb2 (ER+ 1.655+/20.513
versus ER2 149+/2121; ERb+ 24+/221.9 versus ERb2
114.8+/297.1). In Nectin-3, ER+ levels were higher than ER2,
and ERb+ were lower than ERb2 (ER+ 3693+/23052 versus
ER2 655+/2450; ERb+ 259+/2101 versus ERb2 1964+/
212080). This was also true for Nectin-4 (ER+ 0.404+/20.359
versus ER2 0.144+/20.092; ERb+ 0.008+/20.005 versus
ERb2 0.278+/20.092), however, these did not reach signifi-
cance.
Nectin expression in ductal carcinomas
Expression of Nectin-1 and Nectin-2 was higher in ductal car-
cinomas than in all other histological types (Nectin-1: ductal 348+/
2122 versus other 112+/227, p = 0.063; Nectin-2: ductal 104+/
293 versus other 82+/238, p = 0.0037). Ductal carcinomas had
lower levels of Nectin-3 but not Nectin-4, (Nectin-3: ductal
1534+/21177 versus other 2581+/21699, p = 0.6; Nectin-4:
ductal 0.30+/20.15 versus other 0.022+/20.021, p = 0.074).
When considering patient outcome in those with ductal cancer, it
was found that Nectin-1 was increased in those with poor outcome
(with metastasis and death), but reduced with those who had bone
metastasis (alive & well 315+/2135; poor outcome 554+/2360;
bone metastasis 158.2+/294.5, significance not reached). For
Nectin-2, patients with ductal carcinoma who remained alive and
well had higher levels than those with poor outcomes (alive & well
131+/2130; poor outcome 1.357+/20.627; bone metastasis
1.46+/20.48, significance not reached). Patients with ductal
cancer, who remained alive and well, had higher levels of Nectin-3
than those who had poor outcome or bone metastasis (alive & well
390+/2151; poor outcome 324+/2154; bone metastasis 165+/
273.4, significance not reached). This was also the case for
Nectin-4 (alive & well 0.382+/20.207; poor outcome
0.092+20.087; bone metastasis 0.0053+/20.005, p = 0.07, sig-
nificance not reached).
Protein expression and distribution of Nectin-1, -2 and -3
in patient tissues
When paired tumour/background tissues were screened for
Nectin protein expression, there appeared little overall difference
in tumour expression for both Nectin-1 and Nectin-2 (Figure 1H
left and center panels), although both strongly stained tumour
cells, whereas only endothelial cells were strongly stained in
background tissue. However, Nectin-3 was much reduced in
tumour tissues, when compared to background (Figure 1H, right
panel). Further investigation showed that tumour cells had
reduced staining of the cytoplasm but concentrated complexes of
Nectin-3 within the nuclear area (Figure 2 left panel). This was not
the case in cells in background tissues. Due to the unusual
distribution we decided to investigate Nectin-3 further.
Screening of Nectins in human cancer cell lines
PCR primers were initially designed to amplify a 300 bp region
of each Nectin for fast screening of human breast cancer and
endothelial (HECV) cell lines (Figure 3A, Table 1). However, from
the 12 cell lines analysed, there was no correct sized band for
Nectin-1, only MDA-MB-436 and BT-474KC breast cancer cell
lines expressed the correct sized band for Nectin-2, only BT-482
breast cancer cell lines strongly showed the correct band for
Nectin-3 (with very weak bands for MDA-MB-436 and MDA-
MB-231 cells) and Nectin-4 was not correctly expressed in any cell
lines. As we wished to investigate Nectin-3 further, we designed a
number of PCR primer to amplify (a) the full length of the Nectin-
3 coding gene, (b) sequentially larger regions in order to ascertain
where the change in Nectin-3 length of transcript arose (Table 1).
Only BT-482 cells contained the complete length Nectin-3
transcript Figure 4A, top). Of all the regions amplified, only the
regions amplified to produce a 386 bp and an 844 bp fragment
produced the correct products (Figure 3B). All the breast cancer
cells analysed had the correct fragment 386 bp fragment, apart
from MCF-7, ZR-751, BT-549 and MDA-MB-435S cells. Only
MDA-MB-436 cells had the 844 bp fragment. It appears from
these results that Nectin-3 is expressed as a truncated form in
nearly all the human breast cancer cells analysed. Although all
PCR experiments were consistent and carried out a minimum of
three times, we decided to examine the expression of Nectin-3 as
regards to confluency. We chose two breast cancer cells lines:
MDA-MB-231, aggressive cells that only expressed the 386 bp
region and MCF-7 cells, less aggressive and not expressing any
regions of Nectin-3. We extracted mRNA from both cell lines after
growth to reach 25%, 59% and 100% confluency. We were
interested to see that after using the PCR primers amplifying the
386 bp region, that transcript signal increased with increasing
confluency for both cell lines (top, Figure 3C). Moreover, this was
confirmed using Western Blotting (bottom, Figure 3C). We then
decided to over-express Nectin-3 in MDA-MB-231 and MCF-
7cells to observe any changes in cell aggressiveness.
Construction of over expression of Nectin-3
Nectin-3 (complete gene) was cloned into MDA-MB-231 and
MCF-7 human breast cancer cells and expression confirmed using
RT-PCR (Figure 5). Moreover, the human endothelial cell line,
HECV also received the Nectin-3 gene for further investigation
(Figure 3D).
Effect of Nectin-3 overexpression and knock down on
breast cancer cell behavior
Nectin-3 over-expression effected numerous changes on cellular
behavior of the aggressive MDA-MB-231 cells. Motility was
significantly reduced in modified cells (MDAN3) when compared
Figure 1. Expression of the Nectin family in human breast cancer. (A) and (B) Expression of Nectin-1 to -4 and nodal status of breast cancer
patients at the transcript level. (C) and (D) Transcript levels and patient outcome. (E) and (F) Nectin transcript expression and metastatic disease in
human breast cancer. (G) Nectins and patient survival. (H) Immunohistochemistry of Nectin-1 (left), Nectin-2 (middle) and Nectin-3 of representative
patients tissues.
doi:10.1371/journal.pone.0082696.g001
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to MDA-MB-231 wild-type cells (MDAWT), even under the
influence of HGF (hepatocyte growth factor), a well-known
motogen and metastasis factor (p,0.001) Figure 4A. Invasion
was also significantly reduced in MDAN3 cells (p,0.02) Figure 4B.
In vitro growth assays showed that MDAN3 cells were also
significantly slower growing than MDAWT cells (Figure 4C) even
under the influence of HGF (Figure 4D), p,0.05). When looking
at changes in TJ function, it was found that barrier function (as
measured using TER) was significantly increased in MDAN3 cells,
implying that the modified cells had ‘‘tighter’’ TJ. This increased
barrier function was also able to resist the effect of HGF, when
compared to MDAWT cells (Figure 4E), p,0.001. In vivo tumour
growth assays showed that Nectin-3 over-expression was able to
significantly reduced tumour growth over 28 days (Figure 4F),
p,0.05. Knock down of Nectin-3 in MDA-MB-231 cells and
MCF-7 cells resulted in significantly increased motile behavior
(Figure 4G), although there was little additive effect with the
addition of HGF (p,0.005).
Effect of Nectin-3 expression on human endothelial cell
behavior
Over-expression of Nectin-3 effected significant changes on
human endothelial cells. TER was significantly increased in
HECVN3 cells, in comparison to HECVWT (Figure 5A) p, even
under the influence of HGF (Figure 5B) p,0.00001. Paracellular
permeability of HECVN3 cells was reduced compared to
HECVWT, both in treated and non-treated cells (Figure 5C and
D, p,0.05). There was however, no significant difference in
growth rate of Nectin-3 over-expressed cells (Figure 5E and 5F).
Adhesion of HECVN3 cells was significantly reduced compared to
HECVWT/HECVPEF control cells with or without HGF
(Figure 5G), p,005. When a tubule formation assay was carried
out, HECVN3 cells produced tubules with significantly reduced
size, even when treated with HGF, which is a strong angiogenic
factor (Figure 5H), p,0.0001.
Investigation of Nectin-3 protein binding
Due to the discrepancy in expression of Nectin-3, as seen from
RT-PCR, we decided to investigate the binding of Nectin-3 in cells
using two antibodies, (A) which binds to the C-terminus of Nectin-
3 and (B) which binds to an internal region. A number of
immunoprecipitates were then carried out with both antibodies, in
order to determine possible binding partners of Nectin-3.
Figure 6A shows the Immunoprecipitation results of this. There
was, overall, little difference in precipitations between the two
different antibodies used, (A) mapping to the C-terminus of
Nectin-3, (B) mapping to an internal region. Positive precipitations
were observed for a-catenin, ZO-1 (at both the C-teminus and an
Figure 2. Immunohistochemical staining of Nectin-3 in human breast cancer and background tissue to show concentrated Nectin-3
inclusions in tumour sections.
doi:10.1371/journal.pone.0082696.g002
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internal antibody), Nectin-1 and -2, Ezrin, Nectin-4, weakly for
ZO-2 at the internal region, but strongly at the C-teminus, weakly
for ZO-3. There was also interaction to b-catenin, c-catenin and
Moesin (two isoforms showing for (A), weak signal for (B)), Radixin
and Actin. There was also a strong precipitation with MAGI-2.
We also repeated the precipitation with a selection of the
antibodies and probed with Nectin-3 (A) and found strong
precipitation with SIPA-1, ZO-1, Occludin (at an internal region),
CAR, b-catenin and ROCKI (Figure 6B). We were surprised to
see the precipitation with Ezrin and again repeated this
precipitation with both (A) and (B)- again, this was positive
(Figure 6C).
The phosphorylation status of Nectin-3, the effect of HGF
and ROCK inhibitor
As over-expression of Nectin-3 in both MDA-MB-231 and
HECV cells prevented the effect of HGF on cell motility, barrier
function and invasion or tubule formation (all key contributors to
metastasis) we went on to determine if HGF exerted any effect on
the phosphorylation status of the protein. From the Immunopre-
cipitation shown in Figure 6D, it appeared that HGF exerted little
effect on serine phosphorylation of Nectin-3, and no effect on
either tyrosine or threonine phosphorylation. As we were surprised
to observe an interaction between Nectin-3 and ROCKI, we
looked at the effect of the ROCK inhibitor (y-27632) on Nectin-3
phosphorylation. We found an increased tyrosine phosphorylation
of Nectin-3 after ROCKI inhibitor (10 mm) treatment over
30 mins (Figure 5D, middle). There was also a weak increase in
threonine phosphorylation (Figure 5D, bottom). Western blotting
was then carried out to determine any changes in expression of the
other Nectin proteins after Nectin-3 over-expression in MDA-MB-
231 cells (Figure 6 E). It can be seen whilst there was no difference
in protein levels for Nectin-1, both Nectin-2 and Nectin-4 showed
some reduction in levels. We then went on to investigate if Nectin-
3 over-expression caused a change in protein levels of the proteins
we found to have potential binding interactions with Nectin-3
(Figure 6 F). Surprisingly, the over-expression of Nectin-3 in these
Figure 3. Evaluation of Nectin expression in human breast cancer cell lines using RT-PCR (A). Nectin-3 expression in human breast cancer
cell lines showing sequential RT-PCR (B). Effect of cell confluency and Nectin-3 transcript and protein expression as assessed using Western Blotting
(C). Confirmation of over-expression of Nectin-3 in human breast cancer and endothelial (HECV) cell lines (D).
doi:10.1371/journal.pone.0082696.g003
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Figure 4. Effect of Nectin-3 over-expression and knockdown in the human breast cancer cell line MDA-MB-231. (A) Nectin-3 caused
reduced motility, (B) decreased invasion, (C) and (D) reduced in vitro growth (even after treatment with HGF at 40 ng/ml), (E) increased trans-
epithelial resistance (TER) and (F) reduced in vivo tumour growth. Knockdown of Nectin-3 resulted in increased motility in MDA-MB-231 (G) and MCF-
7 (H) cells.
doi:10.1371/journal.pone.0082696.g004
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cells resulted in decreased protein expression of b-catenin, CAR
and SIPA-1. There was no difference in expression of ROCK I
and ZO-1.
Discussion
The Nectin protein family is still little investigated in cancer.
Our study has shown that high levels of Nectin-1 and Nectin-2 is
associated with poor prognosis and patient outcome in human
breast cancer. Previous studies on Nectin-1 have concentrated on
its role in sensitivity to herpes oncolytic therapy in squamous cell
carcinoma, thyroid cancer and head/neck carcinoma [20–21].
However, it has been demonstrated that there is a link between
reduction in breast cancer cell invasion caused by SNAI1-triggered
epithelial to mesenchymal transition (EMT) and the down-
regulation of Nectin-1 [22]. The over-expression of Nectin-2 has
previously been described in breast and ovarian cancer tissues
using gene arrays and immunohistochemistry [13]. The authors
further determined that Nectin-2 was over-expressed in various
breast and ovarian cell lines using flow cytometry, concluding that
Nectin-2 could serve as a target for antibody therapy in these
cancer types. Increased levels of Nectin-2 have also been found to
be a biomarker for poor prognosis and metastatic disease in
squamous cell and adenosquamous carcinoma and adenocarcino-
ma of the gallbladder [23].
We found Nectin-3 and Nectin-4 to be reduced in breast cancer
and associated with good prognosis and patient outcome.
However, in lung adenocarcinoma, it has been reported that
membranous expression of Nectin-3 is an independent prognostic
indicator [17]. Interestingly, the authors demonstrated this was
only true in patients where Nectin-3 did not co-localise with E-
cadherin; where there was co-localisation, patient prognosis was
favourable. In contrast to the results described here, an earlier
study on Nectin-4 using a smaller cohort, described no expression
in normal breast epithelium, but expression in 61% of the ductal
cancers examined and that nearly all ER/PR negative tumours
expressed Nectin-4 [16]. When testing serum from patients, the
authors found there to be a correlation between serum Nectin-4
and disease progression. In ovarian cancer, Nectin-4 has also been
reported to be increased in tumour cells and tissues, compared to
normal [15].
Our immunohistochemical staining for Nectin-3 in human
breast tissues revealed the protein to be concentrated as small
inclusions in the nuclear region. These inclusions were seen only in
cells from tumour tissues. This could have a direct bearing on the
role of Nectin-3 in the cell. Nectin-3 was first described by Satoh-
Horikawa et al. [6]. They found a novel Ca2+independent
homophilic binding cell-cell unit located at cadherin based
adherens junctions. The authors isolated three splicing variants
which were nectin-3a (largest), -3b (middle), and -3c (smallest).
Nectin-3a was found to consist of three extracellular domains, a
transmembrane region and a cytoplasmic tail with a PDZ-binding
motif. Nectin-3a formed a cis-homo-dimer and showed Ca2+
-independent trans-homo-interaction to cause homophilic cell-cell
adhesion. Nectin-3a furthermore showed trans-hetero-interaction
with nectin-1 or -2 but did not form a cis-hetero-dimer with nectin-
1 or -2. Moreover, Nectin-3a interacted with actin and colocalised
with Nectin-2 [6]. In comparison, nectin-3c lacked the C-teminal
PDZ motif and was unable to interact with actin. In our current
study, all four Nectins had aberrant expression in the cancer cells
lines investigated. Nectin-3 was only fully expressed in one breast
cancer cell line (BT-482). Sequential overlapping amplification via
RT-PCR showed that the majority of breast cancer cell lines
expressed the first domain of Nectin-3. This truncated Nectin-3
does not correspond to any of the Nectin-3 spliced variants, being
too short. Interestingly, increased confluency of human breast
cancer cells resulted in increased transcript of Nectin-3.
Over-expression of Nectin-3 in human breast cancer cells
resulted in a significantly reduced aggressive phenotype, cells that
were less motile, less invasive, slower growing; however, these cells
had increase TJ function. In addition, expression of Nectin-3 in
human endothelial cells also imbued cells with increased barrier
function and reduced ability to undergo tubulogenesis. It appears
that Nectin-3 could be involved in barrier function and that the
aberrant expression observed in wild type cells could prevent
correct assembly of cell-cell junctions. Each member of the Nectin
family forms homo-cis-dimers, followed by formation of homo-
trans-dimers, causing cell-cell adhesion [24]. Nectin-3 also forms
hetero-trans-dimers with either Nectin-1 or Nectin2 and the
formation of these is much stronger than that of the homo-
trans-dimers. It has been shown that the first Ig-like domain of
Nectins-1, -2, and -3 contain a highly conserved peptide sequence
that corresponds to aa 118–132, aa 125–139, and aa 142–156,
respectively (6). The authors drew an analogy with E-cadherin,
where this conserved sequence is crucial for trans-interaction
between cells. Nectin-3a does not form a cis-hetero-dimer with
Nectin-1a or -2a and it is likely that a portion(s) of the extracellular
region, which is different from that necessary for trans-interaction,
determines cis-dimerization specificity [6]. Nectins have the
potential to recruit the E-cadherin-beta-catenin complex to the
Nectin based cell-cell adhesion sites through afadin and a-catenin
[25]. Moreover, Nectins have been shown to recruit ZO-1 also
[26]. Fukuhara et al. [27] have shown that Nectin-1 plays a role in
the localisation of TJ components, Claudin-1 and occludin, in the
formation of the junctional process in MDCK cells. Claudin-1 and
occludin accumulated at the apical sites of Nectin-1a-based cell-
cell adhesion sites during the formation of the junctional complex.
The accumulation of Claudin-1 and occludin could be inhibited
by Nectin inhibitors, gD and Nef-3, which inhibited the trans
interaction of Nectin-1a. Nectin inhibitors also impaired the
barrier function of TJ [27]. Such results suggest that trans
interaction of Nectin-1 is necessary for the localisation of Claudin-
1 and occludin as well as the formation of TJs. Claudin-1 and
occludin interact with ZO-1 through its C-terminal and Nectin-1
recruits ZO-1 to the Nectin based cell-cell adhesion sites through
afadin in a cadherin-independent manner [26]. Thus Nectin-1
recruits Claudin-1 and occludin through their cytoplasmic-tail
binding proteins afadin and ZO-1. Nectin-1 is also involved in the
localisation of JAM at TJs [27]. During the formation of cell-cell
junctions, the trans-interaction of Nectins first occurs at the initial
cell-cell contact sites, and then promotes the formation of
cadherin-based AJs and the subsequent formation of claudin-
based TJs [28]. It can therefore be postulated that Nectin-3 has a
hitherto unreported role in the successful organization of TJs. The
Immunoprecipitation experiments we carried out showed a
number of potential binding partners amongst well known TJ
proteins that could suggest a similar role for Nectin-3 in the
recruitment of TJ components to the cell membrane. This could
be an essential mechanism in breast epithelial cells to maintaining
cell adhesion and barrier function. In cancer cells therefore,
aberrant expression of Nectin-3 could lead to the prevention of TJ
protein recruitment, lack of formation of TJs and hence loss of cell-
cell integrity. Increasing evidence has placed TJs as the key
structure that cancer cells must overcome in order to successfully
metastasize [29].
Also of interest was the possible interaction of Nectin-3 with
proteins from the ERM family, i.e. ezrin, radixin and moesin. The
ERM protein family act as molecular cross-linkers between actin
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Figure 5. Effect of Nectin-3 over-expression in the human endothelial cell line, HECV. (A) and (B) Nectin-3 caused increased resistance and
(C) and (D) reduced paracellular permeability. No change was seen in in vitro growth assays (E and F). Nectin-3 over-expression caused reduced
adhesion (G), but increased tubule formation (H).
doi:10.1371/journal.pone.0082696.g005
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filaments and proteins anchored in the cell membrane [30]. They
participate in a complex intracellular network of signal transduc-
tion pathways and play a key role in the regulation of adhesion
and polarity of normal cells through interactions with various
membrane molecules. Ezrin and related molecules are concen-
trated at surface projections such as microvilli and membrane
ruffles where they link the microfilaments to the membrane. Actin
binding proteins allow cross-linking of actin filaments and
regulation of actin filaments prior to cell motility. ERM proteins
are believed to act as membrane organisers and linkers between
plasma membrane molecules such as CD44 and ICAM-2 and the
cytoskeleton [31–32]. There is now compelling scientific and
clinical evidence that adhesion molecules and the ezrin family are
important structures in controlling cell functions such as adhesion
as well as controlling the progressive nature of cancer cells [33]. It
is therefore probable that control of the assembly or disassembly of
Figure 6. Immunoprecipitation study of Nectin-3 (A, an antibody to the C-terminal region; B, an antibody to an internal region) and
proteins that are involved in cell to cell adhesion (A). Immunoprecipitation of relevant proteins probed with Nectin-3 (B). Ezrin precipitation
and confirmation of Nectin-3 interaction (C). Phosphorylation study of Nectin-3 after treatment with HGF (40 ng/ml) and/or the ROCK inhibitor Y-
27632 (D). Effect of Nectin-3 over-expression on the protein expression of Nectin-1, -2 and -4 (E). Effect of Nectin-3 over-expression on the protein
expression of potential binding partners (F).
doi:10.1371/journal.pone.0082696.g006
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cell-cell adhesion and changes in the cell actin cytoskeleton leading
to motility could involve some interaction between Nectin-3 and
ezrin, for example. This is an area that could be fertile for further
research.
The possible interaction between ROCKI and Nectin-3 could
also be another exciting area of research. Changes in the
phosphorylation status of Nectin-3 shown in this current study,
demonstrates that the Y-27632 ROCK inhibitor increased both
tyrosine and threonine phosphorylation. There have been no
studies investigating the phosphorylation status of Nectin-3 and
limited studies on the phosphorylation of other Nectins. Nectin-2d
is tyrosine phosphorylated in response to cell-cell adhesion [8] and
knockdown of afadin or Nectin-3 in NIH3T3 cells caused
relatively rapid suppression of the PDGF (platelet-derived growth
factor)-induced phosphorylation of Akt; moreover, an increase in
the phosphorylation of Akt occurred in afadin- or Nectin-3-
knockdown NIH3T3 cells after treatment with PDGF [34],
suggesting that the Nectin-afadin complex is involved in the
(PDGF)-induced activation of phosphatidylinositol 3-kinase
(PI3K)-Akt signaling for cell survival.
Conclusion
In conclusion, it appears that Nectin family members have
disparate expression in human breast cancer and that the aberrant
expression of Nectin-3 is associated with metastatic disease. The
expression and interaction of Nectin-3 in breast cancer and
endothelial cells indicates that Nectin-3 may be a key component
in the formation of cell junctions and be a putative suppressor
molecule to the invasion of breast cancer cells.
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